Burkholderia pseudomallei, 328
Burn wound impetigo, 367
Burn wound infection, 363–364
bacteremia, 368
causes of, 359
diagnosis of, 364–368
line sepsis, 371
microbial status of, histologic staging of, 367
other infections, 371–372
pneumonia, 369–370
prevention of, 360–363
early excision, 360
sepsis, 368–369
topical antimicrobials and, 361
viruses, 369
CAB.SeeCatheter associated bacteriuria
(CAB)
Calcific aortic stenosis, 227
Calculous cholecystitis
clinical and radiologic diagnosis of, 82–83
mimic of, 83
Camel back fever pattern, 12
Campylobacter jejuni, 330
CA-MRSA.SeeCommunity-acquired
methicillin-resistantStaphylococcus
aureus(CA-MRSA)
Candida albicans, 181, 222, 226, 277, 343
Candidaspp.
anti-TNF therapy and, 382
burn wound infection and, 365, 371
fungal IE and, 222, 233
resistance patterns of, 248
skin infections and, 296
infection, in SOT recipients, 394, 395
Candle wax drippings in fundi, 72
CAP.SeeCommunity-acquired pneumonia
(CAP)
Capnocytophaga canimorsus, 302, 352
infections, 28–29
Carbapenems, 494, 529, 537, 544
Cardiac decompensation, 165
Cardiac output (CO), 130
Cardiobacteriumhominis, 221
Cardiotoxicity, 544
Castleman’s disease, 378
Cat bites,Pasteurellaspp. and, 301–302
Catheter associated bacteriuria (CAB), 498, 514,
515–516
Catheter-related bloodstream infections (CRBSI),
218, 226, 234, 249
in SOT recipients, 403–404
Cat scratch disease (CSD), 70
Cavitary pneumonia
clinicals and radiologic diagnosis of, 94, 95, 96
mimics of, 96, 97
Cavitation, severe CAP and rapid cavitation,
170–173
CCFA.SeeCefoxitin, cycloserine, and fructose agar
(CCFA)
CCHF.SeeCrimean-Congo hemorrhagic fever
(CCHF)
CCU.SeeCritical care unit (CCU)
CDC.SeeCenters for Disease Control and
Prevention (CDC); Centers for Disease
Control (CDC)
See Clostridium difficilediarrhea/colitis
Cefazolin, 312
Cefepime, 190, 494
in trauma patients, 528
Cefoperazone, 537
Cefotaxime, 343, 355
Cefoxitin, cycloserine, and fructose agar
(CCFA), 275
Ceftaroline, 316
Ceftazidime, 544
in critically ill trauma patients, 528
Ceftizoxime, 527
Ceftobiprole, 193, 316, 494
Ceftriaxone, 191, 355, 528
Cellular-mediated immunity (CMI), 138
Cellulitis, 298–299
diagnosis, 299
necrotizing, 302
treatment, 300
Central nervous system (CNS), 514
granulomatous angiitis of, 137
infection
in compromised hosts, 143
in normal hosts, 143
symptoms/signs of, 144
infections and mimic
brain abscess.SeeBrain abscess
cerebritis.SeeCerebritis
encephalitis.SeeEncephalitis
HIVE.SeeHuman immunodeficiency virus
encephalopathy/encephalitis (HIVE)
meningitis.SeeMeningitis
toxoplasmosis.SeeToxoplasmosis
tuberculosis.SeeTuberculosis, CNS
pathogens and disorders
associated with impaired B-lymphocyte-
mediated humoral deficiency, 143
associated with impaired T-lymphocyte/
macrophage–mediated cellular
immunity, 144
Central venous catheter (CVC), 10–12, 498, 516
Central venous catheter (CVC) infections
complications of
S. aureusABE, 210–214
septic thrombophlebitis, 209–214
therapeutic failure, clinical approach
to, 214–215
diagnosis of, 208–209
empiric therapy of, 209
pathogens associated with, 209
risk factors, 209
Cephalosporins, 537, 544
Cerebellar ataxia, physical findings
diagnostic features, 64
noninfectious mimics, 64560 Index